Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · IEX Real-Time Price · USD
19.52
+0.23 (1.19%)
At close: May 3, 2024, 4:00 PM
19.80
+0.28 (1.43%)
After-hours: May 3, 2024, 4:34 PM EDT
Edgewise Therapeutics Employees
Edgewise Therapeutics had 88 employees on December 31, 2023. The number of employees increased by 29 or 49.15% compared to the previous year.
Employees
88
Change (1Y)
29
Growth (1Y)
49.15%
Revenue / Employee
n/a
Profits / Employee
-$1,138,216
Market Cap
1.82B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 29 | 49.15% |
Dec 31, 2022 | 59 | 28 | 90.32% |
Dec 31, 2021 | 31 | 12 | 63.16% |
Dec 31, 2020 | 19 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
UFP Technologies | 3,093 |
Myriad Genetics | 2,700 |
Taro Pharmaceutical Industries | 1,554 |
Schrödinger | 867 |
Alphatec Holdings | 839 |
Supernus Pharmaceuticals | 652 |
Beam Therapeutics | 507 |
EWTX News
- 10 days ago - Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies - Business Wire
- 18 days ago - Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) - Business Wire
- 5 weeks ago - Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session - Business Wire
- 5 weeks ago - Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 - Business Wire
- 2 months ago - Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 - Business Wire
- 2 months ago - Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference - Business Wire
- 2 months ago - Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) - Business Wire